Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: January 6, 2011
Last updated: August 19, 2014
Last verified: August 2014
This trial is conducted in Europe. The aim of this trial is to investigate the safety and pharmacokinetics (the rate at which the body eliminates the trial drug) of NNC 0128-0000-2011 compared to NNC 0128-0000-2021 when given for the first time to healthy human subjects.

Condition Intervention Phase
Congenital Bleeding Disorder
Haemophilia A
Haemophilia B
Drug: NNC 0128-0000-2011
Drug: NNC 0128-0000-2021
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Single-centre, Randomised, Double-blind, Single Dose, Cross-over Trial Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021, Following Intravenous Administration in Healthy Male Subjects

Resource links provided by NLM:

Further study details as provided by Novo Nordisk A/S:

Primary Outcome Measures:
  • Frequency of adverse events (AEs) [ Time Frame: from first trial product administration until maximally 10 weeks after last trial product administration ]

Secondary Outcome Measures:
  • Neutralising antibodies against FVII and/or N7-GP [ Time Frame: from first trial product administration until maximally 10 weeks after last trial product administration ]

Enrollment: 12
Study Start Date: January 2011
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: NNC 0128-0000-2011
Administered as one single i.v. (intravenous) injection, 100 mcg/kg
Experimental: B Drug: NNC 0128-0000-2021
Administered as one single i.v. (intravenous) injection, 100 mcg/kg


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Body weight between 50.0 and 100.0 kg, both inclusive
  • Body mass index (BMI) between 18.0 and 28.0 kg/m2, both inclusive

Exclusion Criteria:

  • Known or suspected hypersensitivity to trial product or related products, such as activated recombinant factor VII
  • Any clinical sign or known history of atherosclerosis or thromboembolic events
  • Renal dysfunction
  • A subject considered at high risk of thromboembolic events
  • Overt bleeding, including from gastrointestinal tract
  • Hepatitis B or C infection
  • Human immunodeficiency virus (HIV) infection
  • Positive test for drugs of abuse or alcohol as well as a history of alcohol or drug abuse within the past 12 months
  • Smoking within 3 months prior to trial start
  • Unable to abstain from alcohol consumption during visits of trial product administration, visit 2 (0-28 days after screening) and visit 3 (2-4 weeks after visit 2)
  • Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, soft drinks such as cola, chocolate) as judged by the investigator (trial physician)
  • Excessive consumption of a diet deviating from a normal diet
  • Blood donation within the last three months prior to screening
  • The receipt of any investigational product within 30 days of trial product administration
  • Participation in any other trial investigating a procoagulant within the last six months prior to screening
  • Strenuous exercise within four days prior trial start
  • Suffers from a life threatening disease
  • Males who are sexually active and not surgically sterilised, who or whose partner are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practise).
  • Subjects at increased cardiovascular risk, including a strong family history of cardiovascular disease
  • Subjects with high fasting cholesterol at trial start
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01272206

United Kingdom
Manchester, United Kingdom, M15 6SH
Sponsors and Collaborators
Novo Nordisk A/S
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
  More Information

Additional Information:
Responsible Party: Novo Nordisk A/S Identifier: NCT01272206     History of Changes
Other Study ID Numbers: NN7128-3729
2010-021286-67 ( EudraCT Number )
U1111-1118-0208 ( Other Identifier: WHO )
Study First Received: January 6, 2011
Last Updated: August 19, 2014

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders
Hemostatic Disorders
Hemophilia B
Blood Coagulation Disorders, Inherited
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked processed this record on May 24, 2017